Lupin Limited Falls Despite Launching Authorised Generic of Ravicti in the U.S

Mumbai, October 24: Lupin Limited’s share price is witnessing negative investor demand today, despite the company announcing that it has launched the authorised generic version of Ravicti in the US. As of 11:05 AM, the shares were down by 0.27%, or 5.30 points, and were trading at ₹1,934.50. Until now, the shares have traded within a range of ₹1,957.80 and ₹1,929.40. The traded volume stood at 1.74 lakh shares, with the company’s market cap at ₹88,602 crore. The shares have their 52-week high at ₹2,402.90 and their 52-week low at ₹1,795.20.

Shares Fall Despite Company Launching Authorised Generic of Ravicti in the U.S

The fall in the share price comes despite the company announcing that it has launched the authorised generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. The drug is for the treatment and management of patients with urea cycle disorders (UCDs) who cannot be managed by acid supplementation or dietary protein restriction alone.

Following the announcement, Lupin’s stock saw some positive demand in the early trade, but soon started to trade lower due to increased selling pressure. Furthermore, the stock has also provided negative returns to investors in the short term. Year-to-date, the stock is down by 17.76%, by 7.60% in the last 6 months, by 2.32% in the last month, but is up by 0.32% in the last week.

REF: https://nsearchives.nseindia.com/corporate/Lupin2_24102025093244_SE_LetterwithPressRelease_24102025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations